Kyver­na lands $319M IPO as au­toim­mune CAR-T field has its mo­ment in the sun

Cal­i­for­nia biotech Kyver­na Ther­a­peu­tics will gar­ner $319 mil­lion from its Thurs­day morn­ing Nas­daq de­but as it rides a small but wel­come wave of in­vestor en­thu­si­asm …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER